Sign in
CompletedNo phase

Written Exposure Therapy Versus Prolonged Exposure: a Non-inferiority Trial

Key facts

Who runs it
VA Office of Research and Development
Where
Boston, Charleston, and Madison, United StatesSee the 3 sites
Trial code
Status
Completed
People taking part
178 people enrolled
Started
9 Sept 2019
Ended
30 Dec 2023
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • trauma-focused treatment
Record updated
18 July 2024

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Veteran status
  • Current DSM-5 diagnosis of PTSD (assessed with the Clinician Administered PTSD Scale for DSM-5; CAPS-5)
  • If taking psychotropic medication, on a stable dose for at least 30 days prior to study entry

Who cannot take part

  • Current psychosis or unstable bipolar disorder diagnosis; determined with the Mini International Neuropsychiatric Interview (MINI)clinician-administered interview
  • Significant cognitive impairment (assessed with the Montreal Cognitive Assessment [MoCA] and clinical judgment)
  • Current engagement psychosocial treatment for PTSD
  • Current diagnosis of substance dependence; abuse will not be excluded; determined with severe combined immunodeficiency (SCID)
  • High suicidal risk; i.e., intent with a plan; assessed with the MINI suicide module

Where in United States

  • VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MABoston, United States
  • Ralph H. Johnson VA Medical Center, Charleston, SCCharleston, United States
  • William S. Middleton Memorial Veterans Hospital, Madison, WIMadison, United States

About the trial

What the trial wants to find out

The goal of this study is to examine whether a brief, exposure-based treatment (Written Exposure Therapy) approach is just as effective in the treatment of posttraumatic stress disorder (PTSD) compared with a more commonly used time-intensive approach called Prolonged Exposure. One hundred and fifty Veterans diagnosed with PTSD will be randomly assigned to either Written Exposure therapy or Prolonged Exposure. Veteran participants will be assessed at pre-treatment, and 10-, 20-, and 30- weeks post first treatment session. Primary outcome measure will be PTSD symptom severity. The secondary outcome measure will be quality of life. In addition, treatment dropout during the first five sessions will be examined. WET is expected to have a lower treatment dropout rate relative to PE.

The 2 groups in the trial

  • written exposure therapyTreatment being tested

    The WET condition consists of 5-7 weekly treatment sessions, with the first session lasting 1 hour and each subsequent session lasting approximately 40 minutes. The first session consists of education about common trauma reactions and the WET rationale. The participant is then given general instructions for completing the trauma narratives and specific instructions for completing the first 30-minute narrative writing session. All WET sessions begin with the therapist reading the specific writing instructions, clarifying any questions the person has, and leaving the instructions with the participant during the 30-minute writing session. Writing instructions begin with a focus on the details of the trauma and then shift to the meaning of the trauma event. After 30 minutes of writing, the therapist stops the writing and conducts a 5-10 minute check-in regarding how the writing session went for the participant.

    Treatment: trauma-focused treatment

  • Prolonged ExposureExisting treatment, for comparison

    Prolonged Exposure (PE) is a 8-15, 90 minute trauma-focused treatment which consists of imaginal and in vivo exposures

    Treatment: trauma-focused treatment

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
An Efficient, Exposure-based Treatment for PTSD Compared to Prolonged Exposure: A Non-inferiority Randomized Trial
Publications
Record updated
18 July 2024